Ex vivo antibody production
US12084681B2 · kind B2 · utility
0Cited by
2References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 19, 2019 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | May 11, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/6054
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides means and methods for producing improved ex vivo B cell cultures with a short doubling time.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.